-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Benzinga·07/27/2026 10:05:29
Listen to the news
BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $27 to $24.